What is Nuvation Bio's SG&A?

Nuvation Bio (NUVB) reported SG&A of $38.31M in Q1 2026.

How has Nuvation Bio's SG&A changed year-over-year?

Nuvation Bio's SG&A increased by 8.2% year-over-year, from $35.39M to $38.31M.

What is the long-term trend for Nuvation Bio's SG&A?

Over 2 years (2023 to 2025), Nuvation Bio's SG&A has grown at a 130.5% compound annual growth rate (CAGR), from $28.53M to $151.56M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Nuvation Bio NUVB SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

PfizerPFE

$2.96B-2.3%

Syndax PharmaceuticalsSNDX

$44.92M+48.6%

BillionToOne, Inc. BLLN

$46.57M+56.0%

Jazz PharmaceuticalsJAZZ

$352.7M-31.4%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

See full

Market cap$2.1B+150%

Enterprise value$2.03B+154%

P/S14.7×-62.0×

Profitability

See full

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's SG&A?: Nuvation Bio (NUVB) reported SG&A of $38.31M in Q1 2026.
How has Nuvation Bio's SG&A changed year-over-year?: Nuvation Bio's SG&A increased by 8.2% year-over-year, from $35.39M to $38.31M.
What is the long-term trend for Nuvation Bio's SG&A?: Over 2 years (2023 to 2025), Nuvation Bio's SG&A has grown at a 130.5% compound annual growth rate (CAGR), from $28.53M to $151.56M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.